Ergosterol biosynthesis in Aspergillus fumigatus: its relevance as an antifungal target and role in antifungal drug resistance by Laura Alcazar-Fuoli & Emilia Mellado
“fmicb-03-00439” — 2013/1/8 — 22:19 — page 1 — #1
MINI REVIEW ARTICLE
published: 10 January 2013
doi: 10.3389/fmicb.2012.00439
Ergosterol biosynthesis in Aspergillus fumigatus: its
relevance as an antifungal target and role in antifungal
drug resistance
Laura Alcazar-Fuoli* and Emilia Mellado
Mycology Reference Laboratory, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Madrid, Spain
Edited by:
Elaine M. Bignell, Imperial College
London, UK
Reviewed by:
JonY. Takemoto, Utah State
University, USA
Jean Paul Latge, Institut Pasteur,
France
*Correspondence:
Laura Alcazar-Fuoli, Mycology
Reference Laboratory, Centro
Nacional de Microbiologia, Instituto
de Salud Carlos III, Carretera
Majadahonda-Pozuelo Km2, 28220
Madrid, Spain.
e-mail: lalcazar@isciii.es
Ergosterol, the major sterol of fungal membranes, is essential for developmental growth
and the main target of antifungals that are currently used to treat fatal fungal infections.
Emergence of resistance to existing antifungals is a current problem and several secondary
resistance mechanisms have been described in Aspergillus fumigatus clinical isolates. A
full understanding of ergosterol biosynthetic control therefore appears to be essential for
improvement of antifungal efﬁcacy and to prevent antifungal resistance. An ergosterol
biosynthesis pathway in A. fumigatus has been proposed with 14 sterol intermediates
resulting in ergosterol and another secondary ﬁnal compound C-24 ethyl sterol. Transcrip-
tomic analysis of the A. fumigatus response to host-imposed stresses or antifungal agents
is expanding our understanding of both sterol biosynthesis and the modes of action of
antifungal drugs. Ultimately, the identiﬁcation of new targets for novel drug design, or the
study of combinatorial effects of targeting sterol biosynthesis togetherwith othermetabolic
pathways, is warranted.
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ANTIFUNGALS TARGETING ERGOSTEROL AND STEROL
BIOSYNTHESIS
Sterols are neutral lipids of eukaryotic cells, among which ergos-
terol is the main component of fungal membranes. Ergosterol is
involved in numerous biological functions such as membrane ﬂu-
idity, regulation, activity and distribution of integral membrane
proteins, and control of the cell cycle (Bard et al., 1993; Goo-
day, 1995). The essential role of sterols in maintenance of cell
membranes make ergosterol and its biosynthetic pathway essen-
tial for fungal growth, and a primary target for most, currently
available, antifungal drugs to treat severe human fungal infec-
tions. Three main classes of antifungal drugs, namely polyenes,
allylamines, and azoles, directly target ergosterol itself, or enzy-
matic steps of its biosynthetic pathway. The polyene amphotericin
B (AMB) has represented, for more than 30 years, the standard
antifungal therapy for invasive aspergillosis (IA). The AMB mode
of action is still poorly understood. It is widely accepted that
AMB kills yeast primarily via channel-mediated membrane per-
meabilization leading to fungal cell death (Ermishkin et al., 1976).
However, recent research suggests that AMB kills yeast by sim-
ply binding ergosterol so that the channel formation represents
a second complementary mechanism that further increases drug
potency and the rate of cell death (Gray et al., 2012). The allylamine
group of antimycotics interferes at the early-stage of ergosterol
biosynthesis by inhibiting the enzyme squalene epoxidase (Erg1).
Although squalene epoxidases from various origins have been
investigated with respect to substrate requirements, cofactors, and
inhibitors, no structural model is available; and the domains
responsible for enzymatic activity and inhibitor interactions are
not well understood (Ruckenstuhl et al., 2007). The cidal action
of allylamines is closely associated with the development of high
intracellular squalene concentrations, which are believed to inter-
fere with fungalmembrane function and cell wall synthesis (Ryder,
1992). Allylamines are not used to treat IA, however potential use
in combination with azoles, polyenes, or echinocandins in the
management of severe drug-resistant or refractory mycoses has
been proposed (Krishnan-Natesan, 2009). Finally, the main cate-
gory of antifungal agents used against Aspergillus is azole drugs,
such as voriconazole (VCZ) and itraconazole, and a new gen-
eration of azoles that includes posaconazole, isavuconazole, and
albaconazole. Azoles revolutionizedmedicalmycology due to their
broad spectrum and reduced toxicity compared to AMB. Azoles
block the ergosterol biosynthesis pathway via inhibition of 14-α
sterol demethylase (Cyp51/Erg11), a key enzyme that removes the
methyl group at position C-14 of precursor sterols. Inhibition of
ergosterol synthesis at this biochemical level results in toxic sterol
accumulation and cell death (Ghannoum and Rice, 1999).
However, although the use of antifungal drugs has increased
survival of patients with invasive fungal disease, the mortality rate
associated with these infections remains extremely high. This sit-
uation becomes more complicated because emerging resistance to
the existing antifungals is a current problem and secondary resis-
tancemechanisms have been described in clinical isolates (Howard
and Arendrup, 2011; Shapiro et al., 2011; van der Linden et al.,
2011a). Full understanding of the ergosterol biosynthesis path-
way in A. fumigatus is essential to new antifungal drug design
and for improving the activity of existing ones. This review sum-
marizes current knowledge about the enzymatic sequence and
regulation of the biochemical reactions involved in ergosterol
biosynthesis with a view to understanding the main mechanisms
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of antifungal resistance to drugs which target ergosterol or its
biosynthesis.
Aspergillus fumigatus ERGOSTEROL BIOSYNTHESIS
PATHWAY
The biosynthesis of ergosterol involves about 20 enzymes and
includes the synthesis of squalene from mevalonate (Ferreira et al.,
2005; Alcazar-Fuoli et al., 2008). This route is well known in Sac-
charomyces cerevisiae which provides a model for studying this
pathway in other eukaryotes (Fryberg et al., 1973). Depletion of
ergosterol biosynthetic gene functions is lethal in S. cerevisiae,
due to complete prevention of ergosterol production. Deviating
from the prototypical pathway described in S. cerevisiae, other
more complex biosynthetic pathways have been proposed in some
fungi and also in plants, suggesting that the enzymatic pathways
of ergosterol biosynthesis are speciﬁc to fungal taxa (Fryberg et al.,
1973; Nes et al., 1989). In A. fumigatus, the study of this pathway
at a genomic level, demonstrated the existence of multiple genes
encoding key enzymes such as two distinct 14-α sterol demethy-
lases (Cyp51A and Cyp51B; Mellado et al., 2001) and three C-5
sterol desaturases (Erg3; Alcazar-Fuoli et al., 2006). The classi-
cal ergosterol biosynthesis route was reconsidered in A. fumigatus
based on the existence of multiple genes which putatively encode
enzymes with the same or duplicated function in the pathway
(Figure 1). Genetic and biochemical analysis of azole suscepti-
ble wild-type strains and a panel of clinical azole resistant strains
identiﬁed a total of 14 sterols showing a similar sterol pattern
composition, with ergosterol as the main sterol for all of them
(Table 1). Eachof the azole resistant strains had adifferent antifun-
gal susceptibility pattern that correlated with different mutations
in the cyp51A gene. The lack of differences between sterols high-
lights the fact that the resistance mechanism in those strains was
target-dependent and not sterol-dependent, as will be discussed
later. Instead, the sterol composition of single enzyme defec-
tive A. fumigatus mutants was rather different depending on the
lacking enzyme (Alcazar-Fuoli et al., 2008). Mutants deleted in
14-α sterol demethylases (cyp51A and cyp51B) had less ergosterol
than the parental strain and accumulated C-4, and C-14 methyl
sterols; mainly eburicol (Figure 1). Accumulation of eburicol,
together with a decrease in ergosterol, was much more prominent
when the cyp51B gene was deleted compared to Δcyp51A strain.
Downstream in the pathway, the synthesis of ergosterol involves
the transformation of fecosterol, consisting of double-bond rear-
rangements in the steroid nucleus and in the side chain, isomeriza-
tion of the double connection in the C-8 to the C-7 followed by the
desaturation at C-5 and C-22, and the reduction of the C-24. The
enzymatic sequence of these three last steps could differ between
fungal taxa and growth conditions (Nes et al., 1989). Single gene
deletion of each of the C-5 sterol desaturases (Erg3A, Erg3B, and
Erg3C) revealed a different sterol proﬁle in terms of total amount
of ergosterol and sterol composition.Again this phenotypewasdif-
ferent depending on the deleted enzyme. While the absence of the
genes erg3A and erg3C did not signiﬁcantly affect total ergosterol
biosynthesis, the deletion of erg3B caused a dramatic ergos-
terol decrease (70%) and a vast accumulation of the Δ7 sterols
(Figure 1). Although the sterol composition revealed differences
according to the enzyme that was deleted, none of the single gene
FIGURE 1 | Ergosterol biosynthetic pathway. Sterols of A. fumigatus
wild-type strain (CM-237), and Δcyp51A, Δcyp51B (marked in green),
Δerg3A, Δerg3B, and Δerg3C (marked in red) derived mutant strains.
Sterols are clustered and represented in cake plots as the percentage of
total sterols: Δ5 sterols (1, 2, 3, 4, 6, 8 in gray), C-4/C-14 methyl sterols (11,
12, 13, 14 in green), Δ7 sterols (5, 7, 9 in red), and ethyl sterols (10 in
purple) according to the sterol identiﬁcation in A. fumigatus (Table 1).
deletions, at 14-α sterol demethylase or C-5 sterol desaturase level,
was lethal for A. fumigatus or inﬂuenced its virulence (Mellado
et al., 2005; Alcazar-Fuoli et al., 2006). This suggests that although
A. fumigatus might use one of the enzymes Cyp51 or Erg3 for nor-
mal growth, this fungal pathogen is able, including during infec-
tion, to adapt and compensate that lack of an enzyme function.
ANTIFUNGAL RESISTANCE MECHANISMS RELATED TO
ERGOSTEROL OR ITS BIOSYNTHETIC PATHWAY
Three of themostwidely used antifungal drugs, triazoles, polyenes,
and allylamines, are aimed at ergosterol, and they are either
fungicidal but toxic to the host (polyenes) or fungi static and
more vulnerable to resistance (triazoles). Triazoles are inhibitors
that target the ergosterol biosynthetic pathway by binding to the
Cyp51 family of cytochrome P450s (14-α sterol demethylases)
causing the depletion of ergosterol biosynthesis and the accumu-
lation of lanosterol or eburicol (Kelly et al., 1995). A. fumigatus
contains two different, but related Cyp51 proteins, encoded by
cyp51A and cyp51B (Mellado et al., 2001) that are functional 14-
α sterol demethylases (Martel et al., 2010; Warrilow et al., 2010).
The lethality caused by double gene deletion has been shown,
although neither gene is itself essential (Mellado et al., 2005; Hu
Frontiers in Microbiology | Fungi andTheir Interactions January 2013 | Volume 3 | Article 439 | 2
“fmicb-03-00439” — 2013/1/8 — 22:19 — page 3 — #3
Alcazar-Fuoli and Mellado Ergosterol biosynthesis and antifungal drug resistance
Table 1 | Relative amount of sterols (% of total sterols) in differentA. fumigatus wild-type (CM-237), cyp51 deleted strains (Δcyp51A Δcyp51B),
and azole resistance mutants strains with different cyp51A point mutations (CM-796:G54V; CM-3269:TRL98H; CM-2159: M220K).
Sterol names Strains
CM-237* Δcyp51A Δcyp51B CM-796* CM-3269* CM-2159*
1) 24-methylcholesta-5,7,9(11),22-tetraen-3β-ol 1.09 3.69 2.74 0.85 1.18 0.92
2) 24-methylcholesta-5,8,22-trien-3β-ol 0.91 0.87 0.77 0.90 0.80 0.85
3) 24-methylcholesta-5,7,9,22-tetraen-3β-ol 0.71 5.69 4.57 0.00 0.00 0.00
4) 24-methylcholesta-5,7,22-trien-3β-ol (Ergosterol) 78.12 59.48 48.82 84.08 83.70 88.44
5) 24-methylcholesta-7,22 (28)-dien-3β-ol 2.62 1.84 1.18 1.51 1.67 1.09
6) 24-methylcholesta-5,7,22,24(28)-tetraen-3β-ol 0.48 0.41 0.25 0.32 0.21 0.28
7) 24-methylcholesta-7,22,24(28)-trien-3β-ol 0.66 1.44 0.71 0.82 0.51 0.20
8) 24-methylcholesta-5,7,24(28)-trien-3β-ol 0.91 0.14 0.34 0.08 0.19 0.16
9) 24-methylcholesta-7,24(28)-dien-3β-ol (Episterol) 1.51 2.55 2.01 3.59 1.84 1.08
10) 24-Ethylcholesta-5,7,22-trien-3β-ol 7.48 5.48 9.26 2.43 6.46 5.10
11) 4,4,14-trimethylcholesta-8,24-dien-3β-ol (Lanosterol) 1.06 1.39 2.87 3.63 0.29 0.18
12) 4α,24-dimethylcholesta-8,24(28)-dien-3β-ol 0.99 2.03 0.98 0.73 0.00 0.82
13) 4,4,14,24-tetramethylcholesta-8,24(28)-dien-3β-ol (Eburicol) 1.14 9.54 21.95 0.41 1.30 0.23
14) 4,4,24-trimethylcholesta-8,24(28)-dien-3β-ol 2.04 5.44 3.56 0.65 0.62 0.65
*Geometric mean of MICs to antifungal agents of A. fumigatus strains: CM-237: ITC (0.25 μg/ml), VRC (0.48 μg/ml), POS (0.06 μg/ml), FLC (1094.55 μg/ml), AMB
(0.26 μg/ml), TRB (5.4 μg/ml); CM-796: ITC (16 μg/ml), VRC (1.19 μg/ml), POS (1.68 μg/ml), FLC (1094.55 μg/ml), AMB (0.15 μg/ml), TRB (2.38 μg/ml; CM-2159: ITC
(16 μg/ml), VRC (1.19 μg/ml), POS (2 μg/ml), FLC (1094.55 μg/ml), AMB (0.3 μg/ml), TRB (3.17 μg/ml); CM-3269: ITC (16 μg/ml), VRC (4 μg/ml), POS (0.5 μg/ml), FLC
(1094.55 μg/ml), AMB (0.2 μg/ml), TRB (2 μg/ml).
et al., 2007). Moreover, the importance of A. fumigatus Cyp51
proteins in sterol biosynthesis and their signiﬁcance in azole sus-
ceptibility have been extensively studied (Alcazar-Fuoli et al., 2008,
2011; Martel et al., 2010). Also, the in vitro and in vivo corre-
lation of azole resistance has been widely documented; with a
clear association of resistant A. fumigatus strain isolation and lack
of patient response to therapy (van der Linden et al., 2011a). A.
fumigatus azole resistance can arise either from modiﬁcation of
the Cyp51A target, or by its overexpression. Resistance acquired
through exposure to azoles in the patientis correlated with cyp51A
single mutations (Diaz-Guerra et al., 2003; Mann et al., 2003;
Nascimento et al., 2003; Mellado et al., 2004; Howard et al., 2006;
Albarrag et al., 2011), while resistance caused by cyp51A over-
expression is speciﬁcally linked to the combination of a single
amino acid substitution (a leucine to histidine change, L98H),
together with the presence of two tandem copies of a 34-bp
sequence in the promoter of the cyp51A gene. This latter type
of resistance mechanism may have evolved in the environment
through the exposure of the fungus to azole fungicides used in
agriculture (Snelders et al., 2008). In isolation the tandem 34-bp
promoter insertions cannot explain the observed azole cross resis-
tant phenotype (Mellado et al., 2007), however recent work has
demonstrated the essentiality of this 34-bp promoter sequence in
maintaining the wild-type expression of cyp51A, and suggested
the presence of other regulatory elements upstream of the tan-
dem insertions (Paul et al., 2012). Further mechanisms of azole
resistance include overexpression of drug transporters of the
ABC- and/or MFS-type (Tobin et al., 1997; Slaven et al., 2002;
Nascimento et al., 2003), however clinically observed resistance
appears thus far to be limited to mutations which modify the
Cyp51A target site. The sterol content of azole resistant A. fumi-
gatus strains bearing different Cyp51A point mutations suggests
that their azole resistant phenotypes are not the result of pertur-
bations of the ergosterol biosynthetic pathway (Table 1). It is more
likely that azole resistance in these variants results from a reduced
afﬁnity of drug binding to the Cyp51A enzyme. In this sense, 3D
protein models of Cyp51A in combination with azoles have pro-
vided the basis to address how point mutations can affect azole
drug resistance (Alcazar-Fuoli et al., 2011; Fraczek et al., 2011).
Regarding the polyene antifungals, the association between A.
fumigatus susceptibility to AMB in vitro and clinical outcome is
unclear. Secondary resistance to AMB is generally not observed,
even in patients whose therapy has failed (Moosa et al., 2002),
yet resistant mutants have been spontaneously induced in the
laboratory (Manavathu et al., 1998) and resistance to AMB is
well documented for many other Aspergillus species (Blum et al.,
2008; van der Linden et al., 2011b; Hadrich et al., 2012). Acquired
resistance to AMB has been most extensively evaluated in yeasts
and is associated with mutations in the ERG3 gene, which is
linked to qualitative and quantitative alterations of membrane
lipids and an absence of ergosterol (Kelly et al., 1997; Morio
et al., 2012). However, the deletion of three independent erg3-
like genes in A. fumigatus did not affect susceptibility to AMB,
despite marked alterations of sterol composition and a decrease
in total ergosterol (Alcazar-Fuoli et al., 2006). Other studies have
determined that neither ergosterol content, cell wall composition,
or lipid peroxidation levels correlate with heightened A. terreus
AMB resistance, only that a higher level of catalase production in
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A. terreus might contribute to AMB resistance since it promotes
oxidative damage of fungal cell membranes through generation of
reactive oxygen species (Blum et al., 2008).
Terbinaﬁne belongs to the allylamine class of antifungals that
inhibit squalene epoxidase (Erg1). Erg1 catalyzes the ﬁrst oxy-
genation step in sterol biosynthesis and is suggested to be one
of the rate-limiting enzymes in this pathway. Alterations in
A. fumigatus erg1 gene dosage can promote terbinaﬁne resis-
tance (Liu et al., 2004), however, the ﬁrst terbinaﬁne resis-
tance mechanism was described in A. nidulans and associated
with the activity of salicylate 1-monooxygenase (salA), a well-
characterized naphthalene-degrading enzyme, suggesting that
resistance could follow degradation of the naphthalene ring
contained in terbinaﬁne (Graminha et al., 2004). Also, a point
mutation, F391L, in the squalene epoxidase enzyme was found to
confer a strong terbinaﬁne resistance phenotype. The equivalent
mutation was introduced into the homologous gene of A. fumi-
gatus resulting in terbinaﬁne resistance (Rocha et al., 2006). Since
terbinaﬁne is not currently used in the management of IA, the
appearance of terbinaﬁne-resistant strains in the clinical setting
is unlikely, however, its potential use in combination with other
antifungal drugs should be considered.
ALTERNATIVES TO IMPROVE ANTIFUNGAL EFFICACY AND
TO MINIMIZE DRUG RESISTANCE
Global gene expression studies identiﬁed that ergosterol biosyn-
thesis is likely to be highly sensitive to environmental perturba-
tions. Among them, adaptation to the host environment when
A. fumigatus initiates disease is particularly interesting. The tran-
scriptome of A. fumigatus during early stages of infection in the
neutropenic murine lung identiﬁed reduced expression of genes
encoding ergosterol pathway functions (Erg11, Erg24, and Erg3)
relative to laboratory cultures (McDonagh et al., 2008).
Although the target site of azole activity is well studied, the role
of other proteins in the mode of action of these drugs in fungi
is poorly understood. Recently, a critical role for SrbA-mediated
regulation of ergosterol biosynthesis and triazole drug interac-
tions in A. fumigatus has been reported (Blosser and Cramer,
2012). SrbA was identiﬁed by transcriptional proﬁling under
hypoxia conditions as a regulator of ergosterol biosynthetic genes
in response to low oxygen levels. The ΔsrbA mutant strain was
attenuated in virulence and it was hypersusceptible to ﬂucona-
zole and VCZ (Willger et al., 2008). Also, several genes encoding
enzymes that require high levels of oxygen were found to be
transcriptionally repressed in the absence of SrbA, including the
enzymes Erg6, Erg11, Erg24, Erg25, and Erg3. The relationship
between ergosterol regulation and hypoxia was also demonstrated
by the analysis of the sterol proﬁle of the ΔsrbA which showed
a decrease in ergosterol levels and accumulation of C-4 methyl
sterols, suggesting a blockage of C-4 demethylation. In addition,
the apparent control of cyp51 transcript levels by SrbA suggests
an additional target for drug development. A role for SrbA in
the development of triazole resistance has also been suggested,
since alterations in this transcription factor or its DNA-binding
afﬁnity could transcriptionally initiate changes that could alter
target abundance and would lead to triazole resistance (Blosser
and Cramer, 2012).
In a similar manner, analysis of sterol composition in
iron-depleted and replete cultures revealed decreased ergosterol
biosynthesis during iron starvation and the accumulation of two
types of sterol intermediates C-4 and Δ7. The genome-wide
expression response of A. fumigatus in a shift from iron-depleted
to iron-replete conditions (10, 30, 60, 120, and 240 min compared
with that from0min) showed that Erg24 andErg25 functionswere
down-regulated for all of the time points, and in contrast Erg11
was up-regulated at 30 and 60 min of iron exposure (Schrettl
et al., 2008). In conditions of iron limitation, A. fumigatus uses
siderophore-assisted iron uptake, which in turn uses mevalonate
as a precursor. The results described above, together with the char-
acterization of functional siderophore deletedmutants, probed the
link between fungal ergosterol and siderophore biosynthesis in A.
fumigatus via the compound mevalonate. The latter would appear
to feed both biochemical pathways (Yasmin et al., 2012). Also,
in hypoxic conditions SrbA was found to activate siderophore-
mediated iron uptake in response to hypoxia and iron starvation in
part by transcriptional activation of another transcription factor,
HapX (Blatzer et al., 2011).
Transcriptional regulation of ergosterol biosynthesis in A.
fumigatus has also been studied under antifungal exposure in labo-
ratory cultures. Microarray analysis indicated down-regulation of
the erg6 geneunder bothAMBandVCZexposure (da Silva Ferreira
et al., 2006; Gautam et al., 2008). Erg6 has a role in the synthesis
of secondary sterols (ethyl sterols), and its down-regulation sug-
gests that A. fumigatus alters the synthesis of secondary sterols in
response toAMBorVCZ.However, different resultswere found for
the A. fumigatus Cyp51-encoding genes, which were both down-
regulated under VCZ treatment and up-regulated with AMB.
These results may indicate the existence of differential responses
for overcoming the distinct stresses imposed by these drugs. In
addition, genes encoding for Erg24, Erg25, and Erg3 were differ-
entially expressed when A. fumigatus cells were cultured in the
presence of VCZ (da Silva Ferreira et al., 2006).
Collectively, the above observations suggest that ergosterol
biosynthesis is prone to perturbation by environmental condi-
tions, and in a manner dependent upon Erg6, Erg11, Erg24, Erg25,
and Erg3 functions, thereby highlighting these gene functions as
alternative or synergic inhibitors of the pathway. An important
ﬁnding in A. fumigatus was the identiﬁcation of C-24 ethyl sterols.
These sterols can also be ﬁnal metabolites of the sterol pathway
and they are predominantly found in higher plants, though absent
in mammalian cells, which cannot alkylate the C-24 of sterols.
In plants C-24 ethyl sterols have multiple roles to play in growth
and development, however, few reports exist on the detection of
24-ethyl sterols in fungi, and their role in A. fumigatus remains
unknown. C-24 alkylation is catalyzed by S-adenosyl-methionine-
sterol-C-methyltransferases (SAMs). In S. cerevisiae the methyla-
tion is catalyzed by erg6 which converts zymosterol into fecosterol,
and at least two methyltransferases are involved in consecutive
methylation reactions leading to 24-ethyl sterols in higher plants
(Bouvier-Nave et al., 1998). In A. fumigatus, only one Erg6 has
been identiﬁed that could transform lanosterol to eburicol and
may also be involved in the production of C-24 ethyl sterols.
The sterol proﬁle analysis of A. fumigatus strains showed that
the synthesis of 24-Ethylcholesta-5,7,22-trien-3β-ol is sensitive to
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pathway perturbations. In a Δcyp51B mutant a lack of ergosterol
is compensated by an increase of 24-Ethylcholesta-5,7,22-trien-
3β-ol, probably because the activity of the pathway becomes
diverted toward the synthesis of alkyl sterols. However, when
erg3B is suppressed, ergosterol levels are decreased together with
24-ethylcholesta-5,7,22-trien-3β-ol, conﬁrming that this enzyme
would also be involved in the desaturation of C-5,7 alkyl sterols.
Genome wide studies are providing us with a very useful plat-
form from which to dissect the linkages between cellular sterol
biosynthesis and other cell functions or metabolic pathways. Such
new ﬁndings might be further explored for novel drug develop-
ment or for possible combinatorial therapeutic strategies to ﬁght
invasive fungal diseases. Among them, genes encoding enzymes
involved in cellular stress, cell wall synthesis, and transport have
been found to be differentially expressed under antifungal expo-
sure or underhost imposed stresses. To conclude, A. fumigatus
is able to synthesize ergosterol, even with suppression of sev-
eral enzymes in the pathway. Biosynthetic control under different
environmental circumstances is observed, demonstrating that
Aspergillus has alternatives to overcome severe drawbacks. There-
fore, the precise knowledge of this complex biosynthetic pathway
could facilitate the future development of novel and more selec-
tive antifungal drugs in order to improve efﬁcacy and to minimize
drug resistance.
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